More recently, the antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd) has significantly improved outcomes in ERBB2/HER2-overexpressing and mutant cancers.16 The gene discussed is ERBB2; the disease is cancer.